TrialCurveICTAN: reconstructed Kaplan–Meier curves
Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Signal Transduct Target Ther. 2025 Aug 28;10:273. doi: 10.1038/s41392-025-02358-w |
|---|---|
| DOI | 10.1038/s41392-025-02358-w |
| Registry | NCT01996098 |
| Phase | Phase 3 |
| Conditions | Lung Cancer |
| Interventions | 6-month Icotinib, 12-month icotinib |
| Sponsor | Sun Yat-sen University |
| Enrolment | 251 |
| Source licence | Figure published under CC BY 4.0 |
Disease-free survival (investigator-assessed) — ITT population
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: 12-month icotinib 63.4 months; 6-month icotinib 60.5 months; Observation 23.5 months. Survival at 18 months: 12-month icotinib 93%; 6-month icotinib 90%; Observation 58%. Hazard ratio 12-month icotinib vs Observation 0.39 (95% CI 0.26–0.59).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| 12-month icotinib | 84 | 39 | 63.4 |
| 6-month icotinib | 84 | 40 | 60.5 |
| Observation | 83 | 56 | 23.5 |
- 12-month icotinib vs Observation: reconstructed HR 0.39 (95% CI 0.26–0.59)
- 6-month icotinib vs Observation: reconstructed HR 0.42 (95% CI 0.28–0.63)
Landmark survival (reconstructed)
| Time | 12-month icotinib | 6-month icotinib | Observation |
|---|---|---|---|
| 6 mo | 100.0% | 100.0% | 96.3% |
| 12 mo | 98.8% | 95.2% | 73.3% |
| 18 mo | 92.9% | 90.5% | 57.6% |
| 24 mo | 84.4% | 83.2% | 47.1% |
| 36 mo | 70.5% | 68.1% | 37.6% |
| 48 mo | 60.9% | 59.7% | 29.1% |
| 60 mo | 50.8% | 50.5% | 24.6% |
Checks against the published figure
- 12-month icotinib median: printed 61.8, reconstructed 63.4 pass
- 6-month icotinib median: printed 63.2, reconstructed 60.5 pass
- Observation median: printed 23.7, reconstructed 23.5 pass
- hazard ratio: printed 0.4, reconstructed 0.389 pass
- hazard ratio: printed 0.41, reconstructed 0.419 pass
- hazard ratio: printed 0.97, reconstructed 0.916 pass
Overall survival — ITT population
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: 12-month icotinib 91.8 months; 6-month icotinib not reached; Observation 71.3 months. Survival at 18 months: 12-month icotinib 99%; 6-month icotinib 96%; Observation 95%. Hazard ratio 12-month icotinib vs Observation 0.58 (95% CI 0.33–0.99).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| 12-month icotinib | 84 | 22 | 91.8 |
| 6-month icotinib | 84 | 21 | not reached |
| Observation | 83 | 32 | 71.3 |
- 12-month icotinib vs Observation: reconstructed HR 0.58 (95% CI 0.33–0.99)
- 6-month icotinib vs Observation: reconstructed HR 0.56 (95% CI 0.32–0.97)
Landmark survival (reconstructed)
| Time | 12-month icotinib | 6-month icotinib | Observation |
|---|---|---|---|
| 6 mo | 100.0% | 100.0% | 100.0% |
| 12 mo | 100.0% | 98.8% | 97.5% |
| 18 mo | 98.8% | 96.4% | 95.1% |
| 24 mo | 97.6% | 95.2% | 90.1% |
| 36 mo | 93.8% | 91.3% | 81.2% |
| 48 mo | 84.0% | 85.9% | 69.7% |
| 60 mo | 74.3% | 74.4% | 64.7% |
Checks against the published figure
- hazard ratio: printed 0.55, reconstructed 0.576 pass
- hazard ratio: printed 0.56, reconstructed 0.557 pass
- hazard ratio: printed 1, reconstructed 1.03 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/ictan-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/ictan-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Signal Transduct Target Ther. 2025 Aug 28;10:273. doi: 10.1038/s41392-025-02358-w doi:10.1038/s41392-025-02358-w. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/ictan
Report a problem with these data
Related trials
- KEYNOTE-671 (stage II subgroup): Event-free survival; Overall survival
- TOPICAL: Overall survival; Progression-free survival
- PRESERVE-003: Overall survival (OS); Progression-free survival (PFS, investigator assessment)
- LUSTRE: Event-free survival; Local control; Overall survival
- Rezivertinib in EGFR-mutated NSCLC with CNS metastases: CNS progression-free survival (BICR)
- CA209-7AL: Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials